 Delayed-Action Preparations
"Delayed-Action Preparations" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Dosage forms of a drug that act over a period of time by controlled-release processes or technology.
| Descriptor ID |
D003692
|
| MeSH Number(s) |
D26.255.210 D27.720.280.210 E02.319.300.253
|
| Concept/Terms |
Controlled-Release Preparations- Controlled-Release Preparations
- Controlled Release Preparations
- Controlled-Release Preparation
- Preparation, Controlled-Release
- Preparations, Controlled-Release
|
Below are MeSH descriptors whose meaning is more general than "Delayed-Action Preparations".
Below are MeSH descriptors whose meaning is more specific than "Delayed-Action Preparations".
This graph shows the total number of publications written about "Delayed-Action Preparations" by people in UAMS Profiles by year, and whether "Delayed-Action Preparations" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 0 | 3 | 3 | | 2023 | 0 | 1 | 1 | | 2021 | 0 | 4 | 4 | | 2020 | 0 | 2 | 2 | | 2018 | 1 | 3 | 4 | | 2016 | 0 | 3 | 3 | | 2015 | 0 | 1 | 1 | | 2013 | 1 | 0 | 1 | | 2012 | 1 | 1 | 2 | | 2011 | 0 | 2 | 2 | | 2010 | 0 | 2 | 2 | | 2009 | 0 | 2 | 2 | | 2008 | 0 | 1 | 1 | | 2007 | 0 | 3 | 3 | | 2005 | 1 | 0 | 1 | | 2004 | 0 | 2 | 2 | | 2002 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 | | 1994 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Delayed-Action Preparations" by people in Profiles over the past ten years.
-
Saunders EC, Budney AJ, Cavazos-Rehg P, Scherer E, Bell K, John D, Marsch LA. Evaluating preferences for medication formulation and treatment model among people who use opioids non-medically: A web-based cross-sectional study. J Subst Use Addict Treat. 2024 Aug; 163:209383.
-
Desai R, Unigwe I, Riaz M, Smith SM, Shukla AM, Mohandas R, Jeon N, Park H. Comparative Safety of Long-Acting vs. Short-Acting Erythropoiesis-Stimulating Agents Among Patients Undergoing Hemodialysis. Clin Pharmacol Ther. 2024 Jul; 116(1):217-224.
-
Camacho X, Schaffer AL, Brett J, Pratt N, Buckley NA, Henry D, Pearson SA. Quality use of publicly subsidised tapentadol in Australia: a population-based analysis. Intern Med J. 2024 Jun; 54(6):941-950.
-
Espay AJ, Hauser RA, Dhall R, Thakkar S, Cloud L, Zeitlin L, Banisadr G, Fisher S, Visser H. Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study. Mov Disord. 2024 Feb; 39(2):428-432.
-
Weiss MD, Surman C, Khullar A, Owens J, He E, Cataldo M, Donnelly G. Effect of a Multilayer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Trial Followed by a 6-Month Open-Label Follow-Up. J Child Adolesc Psychopharmacol. 2021 11; 31(9):623-630.
-
Weiss MD, Cutler AJ, Kollins SH, Donnelly GAE. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension. J Child Adolesc Psychopharmacol. 2021 11; 31(9):610-622.
-
Weiss MD, Surman C, Khullar A, He E, Cataldo M, Donnelly G. Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension. CNS Drugs. 2021 06; 35(6):667-679.
-
Woody GE, Poole S, Yu E, Carroll J, Lynch KG. Extended release injectable naltrexone before vs. after release: A randomized trial of opioid addicted persons who are in prison. J Subst Abuse Treat. 2021 08; 127:108355.
-
Mitchell MM, Schwartz RP, Choo TH, Pavlicova M, O'Grady KE, Gryczynski J, Stitzer ML, Nunes EV, Rotrosen J. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis. Drug Alcohol Depend. 2021 02 01; 219:108422.
-
Weiss MD, Childress AC, Donnelly GAE. Efficacy and Safety of PRC-063, Extended-Release Multilayer Methylphenidate in Adults with ADHD Including 6-Month Open-Label Extension. J Atten Disord. 2021 08; 25(10):1417-1428.
-
Weiss M, Childress A, Mattingly G, Nordbrock E, Kupper RJ, Adjei AL. Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial. J Child Adolesc Psychopharmacol. 2018 10; 28(8):521-529.
-
Varanoske AN, Hoffman JR, Church DD, Coker NA, Baker KM, Dodd SJ, Harris RC, Oliveira LP, Dawson VL, Wang R, Fukuda DH, Stout JR. Comparison of sustained-release and rapid-release ?-alanine formulations on changes in skeletal muscle carnosine and histidine content and isometric performance following a muscle-damaging protocol. Amino Acids. 2019 Jan; 51(1):49-60.
-
Brinkley-Rubinstein L, Zaller N, Martino S, Cloud DH, McCauley E, Heise A, Seal D. Criminal justice continuum for opioid users at risk of overdose. Addict Behav. 2018 11; 86:104-110.
-
Gomes T, Jain S, Paterson JM, Sketris I, Caetano P, Henry D. Trends and uptake of new formulations of controlled-release oxycodone in Canada. Pharmacoepidemiol Drug Saf. 2018 05; 27(5):520-525.
-
Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology. 2016 Apr 05; 86(14 Suppl 1):S13-24.
-
An T, Choi J, Kim A, Lee JH, Nam Y, Park J, Sun Bk, Suh H, Kim CJ, Hwang SJ. Sustained release of risperidone from biodegradable microspheres prepared by in-situ suspension-evaporation process. Int J Pharm. 2016 Apr 30; 503(1-2):8-15.
-
Jennings JA, Beenken KE, Parker AC, Smith JK, Courtney HS, Smeltzer MS, Haggard WO. Polymicrobial Biofilm Inhibition Effects of Acetate-Buffered Chitosan Sponge Delivery Device. Macromol Biosci. 2016 Apr; 16(4):591-8.
-
Stein MA, Sikirica V, Weiss MD, Robertson B, Lyne A, Newcorn JH. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial. CNS Drugs. 2015 Nov; 29(11):953-62.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|